These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 7594517

  • 1. CTL in mice immunized with human mucin 1 are MHC-restricted.
    Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IF.
    J Immunol; 1995 Dec 01; 155(11):5089-94. PubMed ID: 7594517
    [Abstract] [Full Text] [Related]

  • 2. MUC1 peptide epitopes associated with five different H-2 class I molecules.
    Apostolopoulos V, Haurum JS, McKenzie IF.
    Eur J Immunol; 1997 Oct 01; 27(10):2579-87. PubMed ID: 9368613
    [Abstract] [Full Text] [Related]

  • 3. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
    Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF.
    J Immunol; 1997 Dec 01; 159(11):5211-8. PubMed ID: 9548459
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxic T lymphocyte response to minor H-43a alloantigen in H-43b mice. Privileged H-2Kb restriction to the response is not due to immunodominance or epistatic effect but due to Ir gene function of H-2Kb itself.
    Hino T, Ishikawa H, Saito K.
    J Immunol; 1988 Jan 01; 140(1):44-51. PubMed ID: 3121741
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K, Spruill G, Rhoderick J, Spielman J, Savaraj N, Podack ER.
    Cancer Res; 1999 Sep 15; 59(18):4642-50. PubMed ID: 10493519
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
    Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, McKenzie IF.
    J Clin Invest; 1997 Dec 01; 100(11):2783-92. PubMed ID: 9389743
    [Abstract] [Full Text] [Related]

  • 12. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.
    Apasov SG, Sitkovsky MV.
    J Immunol; 1994 Mar 01; 152(5):2087-97. PubMed ID: 8133027
    [Abstract] [Full Text] [Related]

  • 13. Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I.
    Griffiths E, Ong H, Soloski MJ, Bachmann MF, Ohashi PS, Speiser DE.
    Cancer Res; 1998 Oct 15; 58(20):4682-7. PubMed ID: 9788622
    [Abstract] [Full Text] [Related]

  • 14. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
    Tanaka Y, Koido S, Chen D, Gendler SJ, Kufe D, Gong J.
    Clin Immunol; 2001 Nov 15; 101(2):192-200. PubMed ID: 11683578
    [Abstract] [Full Text] [Related]

  • 15. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
    Stepensky D, Tzehoval E, Vadai E, Eisenbach L.
    Clin Exp Immunol; 2006 Jan 15; 143(1):139-49. PubMed ID: 16367945
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.